The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods

Baili, Paolo; Hackl, Monika; Zielonke, N.; Oberaigner, Willi; Eycken, E. Van; Henau, Kris; Valerianova, Z.; Dimitrova, Nadya; Šekerija, Mario; Zvolský, Miroslav; Dušek, Ladislav; Storm, Hans; Engholm, Gerda; Mägi, Margit; Aareleid, Tiiu; Malila, Nea; Seppä, Karri; Velten, Michel; Troussard, Xavier; Bouvier, Véronique; Launoy, Guy; Guizard, A.V.; Faivre, Jean; Bouvier, Anne; Arveux, Patrick; Maynadié, Marc; Woronoff, Anne‐Sophie; Robaszkiewicz, Michel; Baldi, Isabelle; Monnereau, Alain; Trétarre, Brigitte; Bossard, Nadine; Belot, Aurélien; Colonna, Marc; Molinié, F.; Bara, Simona; Schvartz, Claire; Lapôtre-Ledoux, Bénédicte; Grosclaude, Pascale; Meyer, Martin; Stabenow, Roland; Luttmann, Sabine; Eberle, Andrea; Brenner, Hermann; Nennecke, Alice; Engel, Jutta; Schubert-Fritschle, Gabriele; Kieschke, Joachim; Heidrich, Jan; Holleczek, Bernd; Katalinic, Alexander; Jonasson, Jón G.; Tryggvadóttír, Laufey; Comber, Harry; Mazzoleni, Guido; Bulatko, A.; Buzzoni, Carlotta; Giacomin, Adriano; Sardo, Antonella Sutera; Mazzei, A.; Ferretti, Stefano; Crocetti, Emanuele; Manneschi, Gianfranco; Gatta, Gemma; Sant, Milena; Amash, H.; Amati, C.; Baili, Paolo; Berrino, Franco; Bonfarnuzzo, S.; Botta, Laura; Salvo, Francesca Di; Foschi, Roberto; Margutti, C.; Meneghini, Elisabetta; Minicozzi, Pamela; Trama, Annalisa; Serraino, Diego; Zucchetto, Antonella; Angelis, Roberta De; Caldora, M.; Capocaccia, Riccardo; Carrani, E.; Francisci, Silvia; Mallone, Sandra; Pierannunzio, Daniela; Roazzi, Paolo; Rossi, Silvia; Santaquilani, Mariano; Tavilla, Andrea; Pannozzo, M. Natali F.; Bonelli, Luigina; Vercelli, Marina; Gennaro, Valerio; Ricci, Paolo; Autelitano, M.; Randi, Giorgia; Leòn, Maurizio Ponz de; Marchesi, C.; Crimi, Claudia; Fusco, Mario; Vitale, M.F.; Usala, M.; Traina, Adele; Zarcone, Maurizio; Vitale, Flora; Cusimano, Rosanna; Michiara, Maria; Tumino, Rosario; Rossi, Paolo; Vicentini, Massimo; Falcini, Fabio; Iannelli, A.; Sechi, O.; Cesaraccio, Rosaria; Piffer, Silvano; Madeddu, A; Tisano, F.; Maspero, S.; Fanetti, A.C.; Zanetti, Roberto; Rosso, Stefano; Candela, P.; Scuderi, T.; Stracci, Fabrizio; Rocca, Andrea; Tagliabue, Giovanna; Contiero, Paolo; Tos, Angelo Paolo Dei; Tognazzo, S; Pildava, Santa; Smailytė, Giedrė; Calleja, Neville; Micallef, R.; Johannesen, T.B.; Rachtan, Jadwiga; Góźdż, Stanisław; Mężyk, Ryszard; Błaszczyk, Jerzy; Kępska, Kamila; Bielska–Lasota, Magdalena; Lacerda, G. Forjaz de; Bento, Maria José; Antunes, Luís; Miranda, A.; Mayer-da-Silva, A.; Nicula, Florian; Coza, Daniela; Diba, C. Safaei; Primic-Žakelj, Maja; Almar, Enrique; Mateos, Antonio Navareño; Errezola, M.; Larrañaga, Nerea; Torrella-Ramos, A.; García, J.M. Díaz; Marcos-Navarro, A.I.; Marcos‐Gragera, Rafael; Vilardell, L.; Yuste-Sánchez, María José; Molina, Esther; Navarro, Carmen; Chirlaque, María‐Dolores; Moreno‐Iribas, Conchi; Ardanáz, Eva; Galcerán, Jaume; Carulla, Marià; Lambe, Mats; Khan, S.; Mousavi, M.; Bouchardy, Christine; Usel, M.; Frick, Harald; Lorez, Matthias; Ess, Silvia; Herrmann, Christian; Bordoni, Andrea; Spitale, Alessandra; Konzelmann, Isabelle; Ho, Vincent K.Y.; Siesling, Sabine; Coleman, Michael P.; Allemani, Claudia; Rachet, Bernard; Verne, Julia; Easey, N.; Lawrence, Gill; Morán, Teresa; Rashbass, Jem; Roche, M.; Wilkinson, J.; Gavin, Anna; Fitzpatrick, Deirdre; Brewster, David H.; Huws, Dyfed Wyn; White, C.; Otter, Renée

doi:10.1016/j.ejca.2015.08.001

Cited by 100 publications

(74 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estimates of 1-year, 3-year and 5-year relative survival (RS) and estimates of 5-year RS conditional to surviving one year (conditional survival) were derived for patients diagnosed in 2000-2007, by using the complete approach [7].…”

Section: Statistical Analysesmentioning

confidence: 99%

“…The study analysed data of patients followed up to the end of 2008 and diagnosed with invasive malignant cancer of the colon and rectum, anal canal and anus (ICD-O-3 topography codes: C18-C21, morphology codes: 8000/3-9589/3, according to International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [6] Details of the data collection of the EUROCARE-5 study, inclusion criteria for eligible CRs, data standardisation, measures of quality control and the setup of the study database and used methods can be found in the paper of Rossi and colleagues in this monograph [7].…”

Section: Study Databasementioning

confidence: 99%

See 1 more Smart Citation

On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Agius¹,

Innos²,

Eisemann³

et al. 2015

European Journal of Cancer

Self Cite

102

View full text Add to dashboard Cite

Section: Statistical Analysesmentioning

confidence: 99%

Section: Study Databasementioning

confidence: 99%

On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Agius¹,

Innos²,

Eisemann³

et al. 2015

European Journal of Cancer

Self Cite

102

View full text Add to dashboard Cite

“…There have been numerous reports on cancer survival revealing improvements through various therapies, derived from hospital-based datasets (1)(2)(3)(4). However, there are few reports on the general efficiency of cancer health services derived from long-term population-based cancer registration systems (5)(6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

“…These international cancer survival studies (5)(6)(7)10) have provided important information concerning differences in populations observed between and within countries, and valuable insights for future planning and investment by governments in primary prevention activities, early detection initiatives and tertiary care to achieve meaningful cancer control (7). A global coordinative research report of survival from 279 population-based registries was published recently (12), and several nationwide research reports were issued to estimate…”

Section: Introductionmentioning

confidence: 99%

“…Nation-wide population-based cancer registration, such as that found in Europe, makes survival analysis possible, and has revealed the impact of various socio-economic factors, natural histories, health-seeking behaviours, awareness, early detection practices and treatment availability and accessibility on cancer survivorship (5,10,11). In less developed countries, however, there were relatively few datasets to provide population-based cancer survival analyses until the first volume of the International Agency for Research on Cancer's report on Cancer Survival in Developing Countries (6) was published in 1998.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Chen

Zhu

Zhang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Population-based cancer survival is an improved index for evaluating the overall efficiency of cancer health services in a given region. The current study analysed the observed survival and relative survival of leading cancer sites from a population-based cancer registry between 1972 and 2011 in Qidong, China. A total of 92,780 incident cases with cancer were registered and followed-up for survival status. The main sites of the cancer types, based on the rank order of incidence, were the liver, stomach, lung, colon and rectum, oesophagus, breast, pancreas, leukaemia, brain and central nervous system (B and CNS), bladder, blood [non-Hodgkin's lymphoma (NHL)] and cervix. For all malignancies combined, the 5-year observed survival was 13.18% and the relative survival was 15.80%. Females had higher observed survival and relative survival (19.32 and 22.71%, respectively) compared with males (9.63 and 11.68%, respectively). The cancer sites with the highest five-year relative survival rates were the female breast, bladder, cervix and colon and rectum; followed by NHL, stomach, B and CNS cancer and leukaemia. The poorest survival rates were cancers of oesophagus, lung, pancreas and liver. Higher survival rates were observed in younger patients compared with older patients. Cancers of the oesophagus, female breast and bladder were associated with higher survival in middle-aged groups. Improved survival rates in the most recent two 5-year calendar periods were identified for stomach, lung, colon and rectum, oesophagus, female breast and bladder cancer, as well as leukaemia and NHL. The observations of the current study provide the opportunity for evaluation of the survival outcomes of frequent cancer sites that reflects the changes and improvement in a rural area in China.

show abstract

Incidence and Survival of Patients With Conjunctival Melanoma in Europe

et al. 2020

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Conjunctival melanoma (CM) is a rare ocular tumor. Estimates of incidence and survival of patients with CM are important to researchers and policy makers. OBJECTIVE To estimate incidence and survival of patients with CM in Europe. DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study used data from 41 European cancer registries adhering to the RARECAREnet project. All individuals diagnosed as having malignant CM from January 1995 to December 2007 coded according to the International Classification of Diseases for Oncology, Third Edition codes C69.0 (conjunctiva) and 8720-8780 (melanoma) were included. Analysis began March 2019.MAIN OUTCOMES AND MEASURES Trend estimates for incidence and for 5-year relative survival (the ratio of the measured survival of patients to the expected survival in the general population for the same country, age, sex, and calendar year). Crude, age-standardized, and bayesian incidence rates were calculated. Five-year relative survival was calculated by the Ederer II method with the cohort and period approach.RESULTS A total of 724 patients 15 years or older (512 [70.7%] were 55 years or older; 366 [50.6%] were female) were analyzed with an overall crude incidence of CM (per 1 000 000 person/y) of 0.46 (95% CI, 0.42-0.49). Crude incidence was similar in men and women (0.48; 95% CI, 0.44-0.54 and 0.46; 95% CI, 0.41-0.51, respectively) and increased with age. Age-standardized incidence increased over time only in men and was the highest in Norway and the Netherlands (more than 0.70). Only 1 case in 14 years was estimated to occur in Iceland vs about 20 cases per year in large countries such as France and Germany. Percentage of 5-year survival (83.5 overall; 95% CI, 78.6-87.3) was not different between adult and elderly patients but showed large geographical disparities across European regions (range, 66-89) and improved markedly in male patients (from 76 in 1995-1998 to 86 in 2003-2007, with a difference of 10.2 [95% CI, 1.3-19.2]; P < .05) becoming similar to that of women in the last period.CONCLUSIONS AND RELEVANCE Although these data are only available through 2007 and based on registries not uniformly covering the European population, the study provides the first Europe-wide estimates of the incidence and relative survival of patients with CM using population-based data. Geographical differences in survival indicate room for outcome improvement in Southern, Northern, and Eastern European countries.

show abstract

The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods

Cited by 100 publications

References 40 publications

On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Incidence and Survival of Patients With Conjunctival Melanoma in Europe

Contact Info

Product

Resources

About